Product
PB
1 clinical trial
4 indications
Indication
Polycystic Kidney DiseaseIndication
Nephrogenic Diabetes InsipidusIndication
Acquired Nephrogenic Diabetes InsipidusClinical trial
A Multi-center, Open-Label, Exploratory Study to Assess the Efficacy of PB in Decreasing the Urine Output and Increasing the Urine Osmolality in Patients With Hereditary Nephrogenic Diabetes Insipidus, Patients With Autosomal Dominant Polycystic Kidney Disease Treated With Tolvaptan, And Severely Polyuric Patients With Previous Lithium Administration (Serendipity-PB1)Status: Recruiting, Estimated PCD: 2025-09-30